Latest news for Zion Oil & Gas (OTC:ZNOG) Stock

Zion Oil & Gas Inc is a United States-based oil and gas exploration and production company. Zion currently holds one active petroleum exploration license onshore Israel, the Megiddo-Jezreel License covering an area of approximately 99,000 acres.

ZION OIL & GAS INC by Zion Oil & Gas, Inc.

Zion Oil & Gas Inc

<p><strong>Colony Bankcorp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NYSE">CBAN</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:30 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Colony Bankcorp beat estimated earnings by 28.999999999999996%, reporting an EPS of $0.44 versus an estimate of $0.34.</p>
<p>Revenue was up $2.60 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.03 in the previous quarter, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at Colony Bankcorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.30</td>
<td>0.31</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.35</td>
<td>0.34</td>
<td>0.33</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>28.70M</td>
<td>27.80M</td>
<td>27.60M</td>
<td>28.40M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>28.62M</td>
<td>27.91M</td>
<td>28.14M</td>
<td>28.18M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Colony Bankcorp <a href="https://www.benzinga.com/quote/CBAN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

CBAN

Insights into Colony Bankcorp Q4 Earnings

<p><strong>Live Oak Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:30 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Live Oak Bancshares missed estimated earnings by -57.99999999999999%, reporting an EPS of $0.22 versus an estimate of $0.53.</p>
<p>Revenue was up $8.38 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company missed on EPS by $0.27 in the last quarter, resulting in a 10.0% drop share price change the following day.</p>
<p>Here's a look at Live Oak Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.46</td>
<td>0.47</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.28</td>
<td>0.59</td>
<td>0.36</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>123.62M</td>
<td>120.12M</td>
<td>116.66M</td>
<td>116.63M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>129.93M</td>
<td>125.48M</td>
<td>116.21M</td>
<td>119.68M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Live Oak Bancshares <a href="https://www.benzinga.com/quote/LOB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Live Oak Bancshares Q4 Earnings

<p><strong>Cadence Bank</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:30 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Cadence Bank beat estimated earnings by 3.0%, reporting an EPS of $0.7 versus an estimate of $0.68.</p>
<p>Revenue was up $427.55 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.09 in the previous quarter, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at Cadence Bank's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.64</td>
<td>0.61</td>
<td>0.55</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.73</td>
<td>0.69</td>
<td>0.62</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>450.96M</td>
<td>442.65M</td>
<td>427.18M</td>
<td>438.19M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>447.36M</td>
<td>456.98M</td>
<td>437.69M</td>
<td>23.14M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Cadence Bank <a href="https://www.benzinga.com/quote/CADE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CADE

Cadence Bank Q4 Earnings Assessment

News

Concentra Group Holdings Announced The Signing Of A Definitive Agreement To Acquire U.S. Occmed Holdings

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.10 by 1.82 percent.  The company reported quarterly sales of $186.49 million which beat the analyst consensus estimate of $184.95 million by 0.83 percent.  This is a 9.14 percent decrease over sales of $205.24 million the same period last year.</p>


Earnings Beats

CATY

Cathay General Q4 2024 GAAP EPS $1.12 Beats $1.10 Estimate, Sales $186.49M Beat $184.95M Estimate

WIIM

ITRG

Integra Resources shares are trading higher after the company announced gold production updates for 2024 and cited the highest levels of production in 21 years.

<p>Everest Group, Ltd., a global underwriting leader providing best-in-class property, casualty and specialty insurance and reinsurance solutions, today announced that its Board of Directors has appointed Jim Williamson as President and Chief Executive Officer, effective immediately.</p>


Management

Everest Group Appoints Jim Williamson As President And Chief Executive Officer, Effective Immediately.

<p><strong>Moderna Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are trading higher Wednesday after Oracle Chairman <strong>Larry Ellison</strong> discussed the potential of artificial intelligence (AI) to <a href="https://www.benzinga.com/general/biotech/25/01/43117087/bird-flu-update-first-commercial-case-in-georgia-moderna-receives-590-million-to-develop-vaccine">revolutionize health care.</a></p>
<p><strong>What To Know:</strong> Ellison highlighted AI&#8217;s ability to analyze blood tests for early cancer detection, identifying circulating tumor fragments and gene-sequencing cancerous tumors to create individualized vaccines, according to <a href="https://economictimes.indiatimes.com/magazines/panache/oracles-larry-ellison-says-ai-driven-cancer-vaccine-could-be-coming-soon-as-donald-trump-announces-a-500-billion-investment-/articleshow/117446402.cms">Economic Times.</a> </p>
<p>Using AI-driven automation, such mRNA vaccines could be produced robotically within 48 hours, significantly accelerating personalized cancer treatment.</p>
<p>The discussion took place at a White House event, where President <strong>Donald Trump</strong> announced a $500 billion private sector investment in AI infrastructure. The initiative, involving a joint venture called <strong>Stargate by OpenAI, SoftBank and Oracle</strong>, aims to construct large-scale data centers and create over 100,000 jobs. Trump emphasized that the investment is part of a broader strategy to advance AI capabilities in the U.S.</p>
<p>Ellison stated that the first data centers under the Stargate project are already under construction in Texas, with plans for 20 facilities measuring half a million square feet each. These centers will support AI applications in health care, including electronic health record analysis and advanced diagnostic tools.</p>
<p>The announcement potentially reinforced optimism around AI&#8217;s role in transforming medical technologies, boosting investor confidence in Moderna and its potential role in AI-driven healthcare advancements.</p>
<p><strong>MRNA Price Action: </strong>Moderna shares closed Wednesday up 7.27% at $38.50, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22155926/Screenshot-2025-01-22-at-15.58.51-1024x532.png" alt="" class="wp-image-745535" style="width:486px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22155926/Screenshot-2025-01-22-at-15.58.51-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22155926/Screenshot-2025-01-22-at-15.58.51-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22155926/Screenshot-2025-01-22-at-15.58.51-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22155926/Screenshot-2025-01-22-at-15.58.51.png 1432w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/25/01/43143335/amazons-100m-land-deal-launches-its-10-billion-data-center-project-in-ohio">Amazon&#8217;s $100M Land Deal Launches Its $10-Billion Data Center Project In Ohio</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em>.</p>


Government

Health Care

Movers

Tech

MRNA

Moderna Shares Are Up Today: What's Going On?

<p><strong>– Base Rent from Our Industrial Portfolio Now Exceeds 72% of All Base Rent –</strong></p>
<p><strong>–&nbsp;Closes on the Sale of Retail and Health &amp; Fitness Properties for $23 Million and Will Realize Over $6.6 Million in Gains&nbsp;–</strong></p>
<p>GREAT NECK, New York, Jan. 22, 2025 (GLOBE NEWSWIRE) -- One Liberty Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLP#NYSE">OLP</a>), a real estate investment trust focused on net leased industrial properties, today announced the completion of the previously announced acquisition of two Class A industrial properties located in the Mobile, Alabama MSA, for $49 million. The two properties comprise an aggregate of 371,586 square feet and are located on approximately 31 acres. There are four tenants—Simpson Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>), Veyer LLC, a wholly owned subsidiary of The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>), Chadwell Supply, a supplier of materials for the multi-family industry, and DC Safety Sales Co., Inc, a supplier of safety equipment to various industries, including the automotive industry. The aggregate annual base rent is approximately $3.1 million, with approximate annual rental increases ranging from 2.3% to 3.5%, and a weighted average remaining lease term approaching seven years. OLP financed the acquisition with cash and a ten-year $29 million mortgage (interest only for five years and then amortizing on a 30-year schedule) bearing an interest rate of 6.12%.</p>


One Liberty Properties Announces $49M Acquisition Of Two Industrial Properties In Alabama; Sells Retail And Health & Fitness Properties For $23M, Gains $6.6M; Base Rent From Industrial Portfolio Now Exceeds 72%

Inventinva shares are trading higher after the company announced its lanifibranor-combination trial met its primary endpoint in the MASH study.

<p>Colony Bankcorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NASDAQ">CBAN</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.34 by 29.41 percent. This is a 41.94 percent increase over earnings of $0.31 per share from the same period last year.  The company reported quarterly sales of $30.781 million which beat the analyst consensus estimate of $28.900 million by 6.51 percent.  This is a 9.23 percent increase over sales of $28.181 million the same period last year.</p>


Colony Bankcorp Q4 2024 Adj. EPS $0.44 Beats $0.34 Estimate, Sales $30.781M Beat $28.900M Estimate

VNCE

Vince Holding shares are trading higher after the company announced P180 is acquiring a majority stake in the company.

Offerings

ASTS

AST SpaceMobile Announces Proposed Private Offering Of $400M Of Convertible Senior Notes Due 2032

<p>B2Gold Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTO#TSX">BTO</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTG#NYSE">BTG</a>, NSX: B2G))) ("B2Gold" or the "Company") announces that it is offering convertible senior unsecured notes due 2030 (the "Notes") in an aggregate principal amount of US$350 million (the "Offering"). The Company expects to grant the initial purchasers of the Notes an option for a period of 15 days to purchase up to an additional US$52.5 million aggregate principal amount of Notes.</p>
<p>The Company intends to use the net proceeds from the Offering to fund working capital requirements and for general corporate purposes. In order to reduce interest expense, the Company will initially apply the net proceeds to pay down the outstanding balance under the Company's revolving credit facility (the "Revolving Credit Facility") and then subsequently use future draws on the Revolving Credit Facility to fund such working capital requirements and for general corporate purposes.</p>
<p>The interest rate and the initial conversion rate of the Notes will be determined by B2Gold and the initial purchasers and will depend on market conditions at the time of pricing of the Offering. The Notes will bear cash interest semi-annually at a fixed rate and be convertible by holders into common shares of the Company (the "Shares").</p>
<p>B2Gold will have the right to redeem the Notes in certain circumstances and holders will have the right to require B2Gold to repurchase their Notes upon the occurrence of certain events.</p>


TSX:BTO

B2Gold Announces Offering Of $350M Convertible Senior Notes Due 2030

BLBD

Blue Bird Appointed John Wyskiel To The Position Of President And CEO, Effective February 17, 2025. He Will Also Join the Board of Directors On Same Date

LEXX

Lexaria Bioscience Files For Up To $50M Mixed Shelf

<p><strong>Knight-Swift</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:02 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Knight-Swift beat estimated earnings by 9.0%, reporting an EPS of $0.36 versus an estimate of $0.33.</p>
<p>Revenue was down $67.72 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.02 which was followed by a 2.0% drop in the share price the next day.</p>
<p>Here's a look at Knight-Swift's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.28</td>
<td>0.20</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.24</td>
<td>0.12</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.91B</td>
<td>1.83B</td>
<td>1.82B</td>
<td>1.97B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.88B</td>
<td>1.85B</td>
<td>1.82B</td>
<td>1.93B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Knight-Swift <a href="https://www.benzinga.com/quote/KNX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Knight-Swift Q4 Earnings

<p>The Q4 earnings report for <strong>QCR Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) was released on Wednesday, January 22, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>QCR Hldgs beat estimated earnings by 10.0%, reporting an EPS of $1.93 versus an estimate of $1.76.</p>
<p>Revenue was up $5.47 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.26, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at QCR Hldgs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.52</td>
<td>1.40</td>
<td>1.30</td>
<td>1.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.78</td>
<td>1.73</td>
<td>1.59</td>
<td>1.97</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>61.47M</td>
<td>65.25M</td>
<td>63.77M</td>
<td>58.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>59.72M</td>
<td>56.16M</td>
<td>54.70M</td>
<td>55.74M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for QCR Hldgs <a href="https://www.benzinga.com/quote/QCRH/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QCRH

QCR Hldgs Earnings Review: Q4 Summary

<p>Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially to our understanding of the immune mechanisms underlying the effects of nasal foralumab.</p>
<p>The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include modulation of:</p>
<ul>
<li>FoxP3 T regulatory cells (Tregs)</li>
<li>CD4+ and CD8+ central memory T cells</li>
<li>CD14+ and CD14- monocytes</li>
<li>Naïve B cells</li>
</ul>
<p>These pathways are known to be associated with antigen presentation, interferon responses, and other regulatory immune mechanisms.</p>
<p>In this study, single-cell RNA sequencing (scRNAseq) of peripheral blood samples taken before and at three and six months after drug administration has revealed relevant gene expression changes associated with nasal foralumab, which has been associated with a reduction in microglial brain inflammation, as measured by advanced microglial PET scans in these same patients.</p>


Biotech

General

TLSA

Tiziana Life Sciences Announces Discovery Of New Immune Biomarkers In na-SPMS Patients Treated With Nasal Foralumab, Showing Gene Expression Changes After 3 Months

<p><strong>RLI</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>RLI missed estimated earnings by -21.0%, reporting an EPS of $0.41 versus an estimate of $0.52.</p>
<p>Revenue was up $35.56 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.34, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at RLI's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.97</td>
<td>1.34</td>
<td>1.60</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.31</td>
<td>1.72</td>
<td>1.89</td>
<td>1.54</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>389.49M</td>
<td>443.66M</td>
<td>367.78M</td>
<td>357.64M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>401.54M</td>
<td>459.90M</td>
<td>377.63M</td>
<td>330.90M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for RLI <a href="https://www.benzinga.com/quote/RLI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Zion Oil & Gas

News

Latest news for Zion Oil & Gas (OTC:ZNOG) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga